Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin glargine
Drug: insulin degludec

First Posted Date: 2010-06-03

Last Posted Date: 2016-01-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 143

Registration Number: NCT01135992

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Olympia, Washington, United States

A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart
Drug: biphasic insulin aspart 30

First Posted Date: 2010-05-31

Last Posted Date: 2013-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 39

Registration Number: NCT01134224

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2010-05-18

Last Posted Date: 2015-09-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT01125553

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Chula Vista, California, United States

Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: metformin
Drug: glimepiride
Drug: insulin glargine

First Posted Date: 2010-05-14

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 521

Registration Number: NCT01123980

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

A Trial Investigating NN1218 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: NN1218
Drug: insulin aspart

First Posted Date: 2010-05-12

Last Posted Date: 2013-12-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT01121289

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2010-05-12

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 82

Registration Number: NCT01121276

Locations: 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin glargine
Drug: insulin degludec

First Posted Date: 2010-05-03

Last Posted Date: 2017-10-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 66

Registration Number: NCT01114542

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Completed

Conditions: Small for Gestational Age
Foetal Growth Problem

Interventions: Drug: somatropin

First Posted Date: 2010-04-27

Last Posted Date: 2019-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 227

Registration Number: NCT01110928

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency

Completed

Conditions: Adult Growth Hormone Deficiency
Growth Hormone Disorder

Interventions: Drug: somatropin

First Posted Date: 2010-04-22

Last Posted Date: 2015-01-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 387

Registration Number: NCT01109017

A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: NN9925 (oral)
Drug: NN9925 (i.v.)
Drug: placebo

First Posted Date: 2010-03-16

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 70

Registration Number: NCT01087645

Locations: 🇬🇧
Novo Nordisk Investigational Site, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy